Prelude Corporation a breast cancer precision diagnostics company, and Cancer Help Desk, have partnered to provide expert nurse navigation services for women diagnosed with ductal carcinoma in situ (DCIS) breast cancer. This alliance allows for direct engagement between newly diagnosed DCIS patients seeking assistance with clinical options and healthcare professionals trained in breast cancer patient navigation. Studies have shown that many women with DCIS are unsure about the benefits of radiation therapy and need clear guidance to make informed decisions. This novel collaboration within the diagnostic laboratory testing space demonstrates a shared commitment to empowering patients with the tools needed to inform their treatment decision-making and planning processes.
Prelude Corporation is a UCSF start-up based on research done by UCSF inventor, Thea Tlsty, PhD.